Diagnotix B.V.

Diagnotix B.V. specializes in manufacturing reagent sets for laboratory testing. These include kits for detecting and quantifying substances like benzodiazepines, psychotropic medications, melatonin, cardiac medications, tacrolimus, anti-epileptic drugs, nortriptyline, immunosuppressants, catecholamines, and pyruvate. These products are designed to support liquid chromatography-mass spectrometry (LC-MS) analysis, which is widely regarded as a precise method for clinical diagnostics.

Diagnotix B.V. is headquartered in the Netherlands. The company’s location in the Netherlands places it within the European regulatory framework, which governs the development and distribution of its diagnostic products.

Diagnotix B.V.’s devices are listed in the euMDaR (eudamed) registry, which is the European Union’s central database for in vitro diagnostic (IVD) medical devices. Listing in this registry ensures transparency and compliance with EU regulatory requirements for IVDs.

Diagnotix B.V.’s reagent sets fall under two primary classifications: IVD Annex II List B and IVD General. Annex II List B applies to certain high-risk IVDs, while the IVD General classification covers lower-risk devices. These classifications determine the regulatory pathway and requirements for their development, manufacturing, and market placement.

Liquid chromatography-mass spectrometry (LC-MS) is considered the gold standard for clinical diagnostics due to its high sensitivity, specificity, and ability to detect trace amounts of substances in complex biological samples. Diagnotix B.V.’s reagent sets are optimized for LC-MS to ensure accurate and reliable results in therapeutic drug monitoring, toxicology, and metabolic analysis, helping laboratories achieve standardized and high-quality diagnostics.